Price
$18.72
Increased by +0.01%
Dollar Volume (20D)
2.85 M
ADR%
5.05
Earnings Report Date (estimate)
Aug 7, 23 (-1.63)
Market Cap.
495.84 M
Shares Float
15.17 M
Shares Outstanding
26.49 M
Beta
-0.16
Price / Earnings
-3.88
BPR
6.70
20D Range
18.03 22.34
50D Range
18.03 23.05
200D Range
18.03 32.44
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 11, 23 -1.58
Decreased by -20.61%
-1.05
Decreased by -48.07%
Mar 1, 23 -0.93
Increased by +17.70%
-0.96
Increased by +3.26%
Nov 8, 22 -1.18
Decreased by -391.67%
-0.72
Decreased by -88.73%
Aug 8, 22 -1.15
Decreased by -5.65 K%
-1.02
Decreased by -12.50%
May 4, 22 -1.31
Decreased by -98.48%
-0.99
Decreased by -32.65%
Mar 7, 22 -1.13
Decreased by -194.17%
2.57
Decreased by -56.02%
Nov 4, 21 -0.24
Increased by +72.41%
-0.91
Increased by +80.91%
Aug 9, 21 -0.02
Increased by +97.47%
-0.11
Increased by +743.80%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 1.37 M
Increased by +41.65%
-48.45 M
Decreased by -18.85%
Decreased by -3.53 K%
Increased by +16.09%
Dec 31, 22 6.81 M
Increased by +573.39%
-26.41 M
Increased by +15.04%
Decreased by -387.97%
Increased by +87.38%
Sep 30, 22 1.29 M
Decreased by -93.81%
-37.37 M
Decreased by -460.62%
Decreased by -2.89 K%
Decreased by -8.96 K%
Jun 30, 22 1.22 M
Decreased by -95.95%
-37.31 M
Decreased by -8.60 K%
Decreased by -3.07 K%
Decreased by -214.65 K%
Mar 31, 22 970.00 K
Decreased by -91.38%
-40.76 M
Decreased by -124.42%
Decreased by -4.20 K%
Decreased by -2.50 K%
Dec 31, 21 1.01 M
Decreased by -98.31%
-31.09 M
Decreased by -192.40%
Decreased by -3.07 K%
Decreased by -5.58 K%
Sep 30, 21 20.89 M
Increased by +N/A%
-6.67 M
Increased by +71.95%
Decreased by -31.91%
Decreased by N/A%
Jun 30, 21 30.03 M
Increased by +N/A%
-429.00 K
Increased by +98.01%
Decreased by -1.43%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.